|
TELECONFERENCE DESCRIPTION |
|
This interactive course is designed to provide the participant
with a knowledge of the requirements for dissolution instrument
qualification, an area which has been changing rapidly over the
last few years. Both the use of USP Performance Verification
Tablets and mechanical approaches will be discussed, as well as
the requirements presented in the USP and in a recent FDA
Guidance. Pitfalls in the performance of the tests as well as
instrument issues which are not addressed by the Qualification
procedures will be addressed.
Finally, some of the practical
suggestions that can minimize both PVT and product failures will
be presented. There will be ample opportunity for participant
questions.
Learning Objectives:
Upon completion of this course the learner should
-
Identify the approaches to dissolution
instrument qualification and the requirements
expressed by USP and by FDA.
-
Perform the qualification procedures with
techniques that will minimize qualification
failures.
-
Evaluate and document the qualification results,
and understand the potential impact of marginal
results.
-
Understand some of the issues which are not
addressed by the current qualification
procedures.
-
Be aware of some of the practical considerations
that can affect routine dissolution testing
results, even with well qualified instruments.
|
| AREAS
COVERED IN THE SEMINAR |
-
Basis for Qualification.
-
Calibration and qualification of
equipment requirements bin GMP
guidelines for FDA and EMA.
-
USP General Chapter <1058>
Analytical Instrument
Qualification.
-
USP General Chapter <711>
Dissolution refers to
Performance Verification Test.
-
Approaches to Dissolution Instrument
Qualification.
-
More challenging due to
chemical, physical and temporal
factors affecting results.
-
Mechanical specifications
available for vessels, stiffing
units and assembled instrument.
-
USP Reference Tablets allow
holistic evaluation of
apparatus.
-
Recent Changes.
-
FDA Guidance and FIP Position
Paper on Mechanical
Qualification.
-
USP changes in acceptance
criteria from individuals to
mean and RSD.
-
Common Pitfalls.
-
Training.
-
Desecration.
-
Vessel geometry.
-
Procedure details: filter
qualification, dropping tablets,
etc.
-
Responding to failures.
-
Recommendations.
-
Make informed decisions about
how instruments will be
qualified, and by whom.
-
Training.
-
Document detailed procedures,
methods, response to failures.
-
Questions and discussion.
|
|
WHO WILL BENEFIT |
|
This webinar will provide valuable assistance to all drug
companies/ manufacturing sites. Those that would benefit most
would be:
-
Chemists (Research, Quality Control, CRO)
involved with residual solvents testing and
their managers,
-
Regulatory affairs/CMC personnel responsible for
documenting compliance with residual solvents
requirements
-
Laboratory managers and staff
-
Analysts
-
QA/QCU managers and personnel
-
Training department
-
Documentation department
-
Consultants
|
|
INSTRUCTOR PROFILE |
|
Greg Martin, is
President of Complectors Consulting ( www.complectors.com )
which provides consulting and training in the area of
Pharmaceutical Analytical Chemistry. He has particular
interest in QbD/Lean approaches to dissolution testing, impurity
methods, method lifecycle (development/validation/transfer) and
instrument qualification, and is passionate about using good
science and sound logic to achieve high quality results,
consistent with cGMPs, while minimizing resources.
Mr.
Martin has over 25 years experience in the pharmaceutical
industry and was Director of Pharmaceutical Analytical Chemistry
(R&D) for a major PhRMA company for a number of years.
In
addition, he has volunteered for the USP for over 10 years, and
currently serves as Vice Chair of the General Chapters –
Physical Analysis Expert Committee, and serves on Expert Panels
on Validation and Verification, Weights and Balances and Use of
Enzymes for Dissolution Testing of Gelatin Capsules.
He is
also Chair-elect of the AAPS In Vitro Release and Dissolution
Testing Focus Group. He serves on the Editorial Advisory
Board of the Journal of Validation Technology and Journal of GXP
Compliance.
|
| REGISTER |
|
Registration - Session Only: $349.00
CD Recording Only: $599.00
|
|
Upcoming Teleconferences
Regulatory Perspectives of Clinical Project
Management: Meeting FDA Requirements for Clinical Trials
Feb. 28, 2012
Registration - Session Only: $299.00
CD Recording Only: $499.00
Learn More
Defending Against an OFAC Investigation
Feb. 28, 2012
Registration - Session Only: $199.00
CD Recording Only: $399.00
Learn More
Solutions to the Challenges of Phase I and FIM
Studies in Today's World
Feb. 29, 2012
Registration - Session Only: $299.00
CD Recording Only: $499.00
Learn More
DMR & DHR - What is Really Required
Feb. 29, 2012
Registration - Session Only: $299.00
CD Recording Only: $549.00
Learn More
|